Inventor · disambiguated record
Yutian Wei
Also filed as: WEI YUTIAN
14 granted patents·9 pending applications·57 citations·filing 2018–2025
91Inventor score
Files withCELLULAR BIOMEDICINE GROUP INC8ABELZETA INC6CELLULAR BIOMEDICINE GROUP HK LTD6SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD3
Top patents by PatentIndex Score
23 records- 0196US11472858B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2021·Granted Oct 18, 2022·7 cites·4 claims
- 0296US11439665B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2021·Granted Sep 13, 2022·8 cites·4 claims
- 0395US11633430B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2022·Granted Apr 25, 2023·7 cites·5 claims
- 0495US11618778B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2022·Granted Apr 4, 2023·7 cites·6 claims
- 0595US11608369B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2022·Granted Mar 21, 2023·7 cites·6 claims
- 0695US11207349B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2020·Granted Dec 28, 2021·7 cites·5 claims
- 0794US11066457B2Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2018·Granted Jul 20, 2021·8 cites·8 claims
- 0893US12311022B2Bispecific chimeric antigen receptors targeting CD20 and BCMAABELZETA INC·Filed 2024·Granted May 27, 2025·2 cites·6 claims
- 0992US12458667B2Bispecific chimeric antigen receptors targeting CD20 and BCMAABELZETA INC·Filed 2024·Granted Nov 4, 2025·1 cites·4 claims
- 1090US12448432B2Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofABELZETA INC·Filed 2022·Granted Oct 21, 2025·1 cites·10 claims
- 1188US11498973B2BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2021·Granted Nov 15, 2022·1 cites·4 claims
- 1285US2025136707A1Bispecific chimeric antigen receptors targeting cd20 and bcmaABELZETA INC·Filed 2024·Application pending·0 cites
- 1382US11142581B2BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereofCELLULAR BIOMEDICINE GROUP HK LTD·Filed 2020·Granted Oct 12, 2021·1 cites·7 claims
- 1481US2023242613A1Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2023·Application pending·0 cites
- 1581US2024139243A1Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2023·Application pending·0 cites
- 1678US2025262243A1Bispecific chimeric antigen receptors targeting cd20 and bcmaABELZETA INC·Filed 2025·Application pending·0 cites
- 1772US12338494B2Reagent and method for fluorescence quantitative real-time PCR detection of RCLABELZETA INC·Filed 2023·Granted Jun 24, 2025·0 cites·7 claims
- 1867US2023053305A1BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application ThereofSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2022·Application pending·0 cites
- 1964US11697848B2Reagent and method for fluorescence quantitative real-time PCR detection of RCLCELLULAR BIOMEDICINE GROUP INC·Filed 2019·Granted Jul 11, 2023·0 cites·7 claims
- 2053US2023212255A1Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2021·Application pending·0 cites
- 2150US2023104705A1Combined chimeric antigen receptor targeting cd19 and cd20 and application thereofCELLULAR BIOMEDICINE GROUP INC·Filed 2020·Application pending·0 cites
- 2249US2023181640A1Anti-bcma antibodies and chimeric antigen receptorsSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
- 2349US2023144447A1Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereofSHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yutian Wei files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →